China has authorized the use of Novo Nordisk’s well-known weight-loss medication Wegovy, the Danish pharmaceutical behemoth announced.
Beijing has approved the ground-breaking treatment for those who are overweight or obese and have at least one weight-related ailment, according to the corporation, which is the largest in Europe based on market capitalization. The company confirmed this to AFP on Tuesday.
When Wegovy will be formally introduced in China remained unclear. At constant exchange rates, Novo Nordisk’s sales increased by 11% in China last year.
The second-most populous country in the world’s patent expires in 2026.
Wegovy is credited with leading a revolution in the treatment of obesity, a key contributor to ill health in the developed world, based on the semaglutide molecule.
Wegovy has also been approved to treat adult patients with heart disease who are overweight or obese in the United States, the group’s largest market for this kind of product.
